Background <p>Chronic kidney disease (CKD) and metabolic dysfunction–associated steatotic liver disease (MASLD) have been associated with an increased risk of cardiovascular disease.</p> Objective <p>This study seeks to examine the prognostic value of the coexistence of CKD and MASLD in patients presenting with acute myocardial infarction (AMI).</p> Methods <p>This cohort study describes the clinical characteristics and long-term outcomes of patients following AMI, stratified by the presence of CKD and MASLD. A Kaplan–Meier curve was constructed for 30-day mortality. Cox regression analysis was used to investigate independent predictors of long-term all-cause mortality, adjusted for age, sex, ethnicity, previous AMI, AMI type, and left ventricular ejection fraction (LVEF).</p> Results <p>A total of 6757 patients with AMI were examined. Those with coexisting CKD and MASLD (CKD(+)/MASLD(+)) had the highest rates of obesity (97.7%, <i>p</i> &lt; 0.001), type 2 diabetes mellitus (85.7%, <i>p</i> &lt; 0.001), hypertension (92.7%, <i>p</i> &lt; 0.001), dyslipidemia (84.1%, <i>p</i> &lt; 0.001), and previous stroke (17.8%, <i>p</i> &lt; 0.001). On discharge, this group was least likely to be prescribed angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) (<i>p</i> &lt; 0.001) and statins (<i>p</i> &lt; 0.001). Additionally, this group had the highest rates of cardiac arrest (5.9%, <i>p</i> = 0.014), cardiogenic shock (15.5%, <i>p</i> &lt; 0.001), and 30-day all-cause mortality (17.8%, <i>p</i> &lt; 0.001). Cox regression demonstrated that the CKD(+)/MASLD(+) (HR 2.412, 95% CI 1.946–2.990, <i>p</i> &lt; 0.001) and CKD(+)/MASLD(−) (HR 2.108, 95% CI 1.789–2.482, <i>p</i> &lt; 0.001) phenotypes were independent predictors of mortality.</p> Conclusions <p>CKD (+)/MASLD(+) embodied a higher metabolic burden and was the strongest independent predictor of mortality in AMI, with higher rates of cardiac arrest and cardiogenic shock. Further studies of early intervention in this group could help to improve outcomes.</p> Graphical abstract <p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Long-term prognosis of coexistent metabolic dysfunction–associated steatotic liver disease and chronic kidney disease following acute myocardial infarction

  • Audrey Zhang,
  • Gwyneth Kong,
  • Grace Cao,
  • Yiming Chen,
  • Vickram Vijay Anand,
  • Jaycie Koh,
  • Yip Han Chin,
  • Bryan Chong,
  • Andie H. Djohan,
  • Horng-Ruey Chua,
  • Siew Pang Chan,
  • Anurag Mehta,
  • Mark Muthiah,
  • Mark Yan-Yee Chan,
  • Poay-Huan Loh,
  • Nicholas W. S. Chew

摘要

Background

Chronic kidney disease (CKD) and metabolic dysfunction–associated steatotic liver disease (MASLD) have been associated with an increased risk of cardiovascular disease.

Objective

This study seeks to examine the prognostic value of the coexistence of CKD and MASLD in patients presenting with acute myocardial infarction (AMI).

Methods

This cohort study describes the clinical characteristics and long-term outcomes of patients following AMI, stratified by the presence of CKD and MASLD. A Kaplan–Meier curve was constructed for 30-day mortality. Cox regression analysis was used to investigate independent predictors of long-term all-cause mortality, adjusted for age, sex, ethnicity, previous AMI, AMI type, and left ventricular ejection fraction (LVEF).

Results

A total of 6757 patients with AMI were examined. Those with coexisting CKD and MASLD (CKD(+)/MASLD(+)) had the highest rates of obesity (97.7%, p < 0.001), type 2 diabetes mellitus (85.7%, p < 0.001), hypertension (92.7%, p < 0.001), dyslipidemia (84.1%, p < 0.001), and previous stroke (17.8%, p < 0.001). On discharge, this group was least likely to be prescribed angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) (p < 0.001) and statins (p < 0.001). Additionally, this group had the highest rates of cardiac arrest (5.9%, p = 0.014), cardiogenic shock (15.5%, p < 0.001), and 30-day all-cause mortality (17.8%, p < 0.001). Cox regression demonstrated that the CKD(+)/MASLD(+) (HR 2.412, 95% CI 1.946–2.990, p < 0.001) and CKD(+)/MASLD(−) (HR 2.108, 95% CI 1.789–2.482, p < 0.001) phenotypes were independent predictors of mortality.

Conclusions

CKD (+)/MASLD(+) embodied a higher metabolic burden and was the strongest independent predictor of mortality in AMI, with higher rates of cardiac arrest and cardiogenic shock. Further studies of early intervention in this group could help to improve outcomes.

Graphical abstract